EP1411966A4 - Method for treating secondary tissue degeneration associated with central nervous system injury - Google Patents

Method for treating secondary tissue degeneration associated with central nervous system injury

Info

Publication number
EP1411966A4
EP1411966A4 EP02746998A EP02746998A EP1411966A4 EP 1411966 A4 EP1411966 A4 EP 1411966A4 EP 02746998 A EP02746998 A EP 02746998A EP 02746998 A EP02746998 A EP 02746998A EP 1411966 A4 EP1411966 A4 EP 1411966A4
Authority
EP
European Patent Office
Prior art keywords
nervous system
central nervous
system injury
tissue degeneration
secondary tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02746998A
Other languages
German (de)
French (fr)
Other versions
EP1411966A2 (en
Inventor
Hans S Keirstead
Thomas E Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1411966A2 publication Critical patent/EP1411966A2/en
Publication of EP1411966A4 publication Critical patent/EP1411966A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02746998A 2001-07-12 2002-07-12 Method for treating secondary tissue degeneration associated with central nervous system injury Withdrawn EP1411966A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30502501P 2001-07-12 2001-07-12
US305025P 2001-07-12
PCT/US2002/022201 WO2003006045A2 (en) 2001-07-12 2002-07-12 Cxcl10 treatment of secondary tissue degeneration

Publications (2)

Publication Number Publication Date
EP1411966A2 EP1411966A2 (en) 2004-04-28
EP1411966A4 true EP1411966A4 (en) 2005-06-01

Family

ID=23178982

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02746998A Withdrawn EP1411966A4 (en) 2001-07-12 2002-07-12 Method for treating secondary tissue degeneration associated with central nervous system injury

Country Status (5)

Country Link
EP (1) EP1411966A4 (en)
JP (2) JP2005501036A (en)
AU (1) AU2002316674B2 (en)
CA (1) CA2452544A1 (en)
WO (1) WO2003006045A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411966A4 (en) * 2001-07-12 2005-06-01 Univ California Method for treating secondary tissue degeneration associated with central nervous system injury
KR20130133302A (en) 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses
JP2010013355A (en) * 2006-10-19 2010-01-21 Stelic Institute Of Regenerative Medicine Myocardial injury-controlling agent
US8258267B2 (en) 2007-02-28 2012-09-04 Novimmune S.A. Human anti-IP-10 antibodies uses thereof
JP5963233B2 (en) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Medicament for treating or preventing HTLV-1-related myelopathy and method for confirming therapeutic effect of antibody therapy using said medicament
CN108602885B (en) 2015-11-30 2022-05-24 百时美施贵宝公司 Anti-human IP-10 antibodies and uses thereof
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011218A1 (en) * 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
WO2002098346A2 (en) * 2001-06-05 2002-12-12 Rappaport Family Institute For Research In The Medical Sciences Method and pharmaceutical composition for the treatment of multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407209B1 (en) * 1986-04-15 2002-06-18 Novartis Ag Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
AU2001288286B2 (en) * 2000-08-18 2007-05-10 The Regents Of The University Of California Methods for treating demyelinating diseases
EP1411966A4 (en) * 2001-07-12 2005-06-01 Univ California Method for treating secondary tissue degeneration associated with central nervous system injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011218A1 (en) * 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
WO2002098346A2 (en) * 2001-06-05 2002-12-12 Rappaport Family Institute For Research In The Medical Sciences Method and pharmaceutical composition for the treatment of multiple sclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILLESPIE G ET AL: "Reducing the T cell response to central nervous system injury decreases posttraumatic degeneration", 2001, SOCIETY FOR NEUROSCIENCE ABSTRACTS, VOL. 27, NR. 2, PAGE(S) 2036, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, ISSN: 0190-5295, XP001205706 *
MCTIGUE DANA M ET AL: "Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 53, no. 3, 1 August 1998 (1998-08-01), pages 368 - 376, XP002322021, ISSN: 0360-4012 *
WOJCIK WALTER J ET AL: "Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 278, no. 1, 1996, pages 404 - 410, XP009045589, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
EP1411966A2 (en) 2004-04-28
WO2003006045A2 (en) 2003-01-23
CA2452544A1 (en) 2003-01-23
AU2002316674B2 (en) 2007-09-13
WO2003006045A3 (en) 2003-12-18
JP2006008705A (en) 2006-01-12
JP2005501036A (en) 2005-01-13

Similar Documents

Publication Publication Date Title
HK1054872A1 (en) Brain, spinal and nerve injury treatment
PL373626A1 (en) Treatment for central nervous system disorders
EP1545700A4 (en) Methods for treating central nervous system damage
EP1328186A4 (en) Methods for treating various eye disorders
EP1701664A4 (en) System and method for treating tissue
EP1411849A4 (en) Apparatus and methods for treating tissue
AU2003297761A1 (en) Methods for treating neurological language disorders
EP1414464A4 (en) Method for treating glaucoma v
EP1476147A4 (en) Methods for treating eye disorders
EP1465968A4 (en) Methods for treating deodorizer distillate
EP1409015A4 (en) Methods for treating or preventing skin disorders using cd2-binding agents
EP1267903A4 (en) Methods for treating glaucoma
AU2003300042A1 (en) Method and system for treating depressive and anxiety disorders
HK1047050A1 (en) Methods for treating mild cognitive impairment
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
AU2003222022A8 (en) Methods for treating deodorizer distillate
IL163993A0 (en) Method for treating cognitive disorders
EP1411966A4 (en) Method for treating secondary tissue degeneration associated with central nervous system injury
EP1695061A4 (en) Method for treating neurological disorders
HK1066161A1 (en) Method for treating primary insomnia
IL162053A0 (en) Method for the treatment of bone disorders
AUPQ614200A0 (en) Method for treating chronic spinal cord injury
EP1359910A4 (en) Method for treating glaucoma ii b
GB2397018B (en) Combination therapy for treating disease
AU2003228813A8 (en) Methods for treating neuronal disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040109

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050420

17Q First examination report despatched

Effective date: 20050719

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091027